Publication
NID2 drives paclitaxel resistance in triple-negative breast cancer via an LDHA-lactate-histone lactylation axis.
Siliang Wang, Yitong Wang, Kaicheng Bao, Siyu Chen, Guoqing Song, Yi Zhao
Cellular signallingDec 1, 2026PMID 42624343doi:10.1016/j.cellsig.2026.112822 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Paclitaxel resistance remains a major barrier to effective treatment of triple-negative breast cancer (TNBC). Nidogen-2 (NID2), an extracellular matrix protein, has been implicated in tumor progression, but its contribution to taxane response is unclear. Here, we integrate patient-derived evidence…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.